iOnctura has secured EUR 80 million (~USD 85.6 million) in a Series B funding round led by Syncona Limited, with participation from EIC Fund, M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. This brings the company's total funds to ~USD 128 million.
The secured funding will accelerate the development of iOnctura's lead candidate, roginolisib, to treat uveal melanoma (UM). The company claimed that in a Phase Ib clinical trial, roginolisib showed long-term safety and promising efficacy in treating UM, with sustained clinical activity observed over several months.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.